Collegium Pharmaceutical, Inc. (COLL)

NASDAQ: COLL · IEX Real-Time Price · USD
35.45
+0.05 (0.14%)
Apr 17, 2024, 4:00 PM EDT - Market closed
0.14%
Market Cap 1.13B
Revenue (ttm) 566.77M
Net Income (ttm) 48.16M
Shares Out 31.96M
EPS (ttm) 1.29
PE Ratio 27.48
Forward PE 11.32
Dividend n/a
Ex-Dividend Date n/a
Volume 248,573
Open 35.47
Previous Close 35.40
Day's Range 34.76 - 35.75
52-Week Range 20.83 - 40.95
Beta 1.05
Analysts Buy
Price Target 38.60 (+8.89%)
Earnings Date May 2, 2024

About COLL

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a bucc... [Read more]

Sector Healthcare
IPO Date May 7, 2015
Employees 197
Stock Exchange NASDAQ
Ticker Symbol COLL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for COLL stock is "Buy." The 12-month stock price forecast is $38.6, which is an increase of 8.89% from the latest price.

Price Target
$38.6
(8.89% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026

STOUGHTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty pharmaceutical company committed to improving the l...

6 days ago - GlobeNewsWire

Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results

– Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million – – Delivered Record...

7 weeks ago - GlobeNewsWire

Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

STOUGHTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people li...

2 months ago - GlobeNewsWire

Appeals Court Upholds PTAB's Finding of Invalidity of Purdue's 961 Patent

STOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the U.S. Court of Appea...

5 months ago - GlobeNewsWire

Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people li...

5 months ago - GlobeNewsWire

Collegium Reports Third Quarter 2023 Financial Results

– Q3'23 Net Revenue of $136.7 Million, Up 8% Year-over-Year – – Q3'23 GAAP Net Income of $20.6 Million vs. Q3'22 GAAP Net Income of $0.5 Million – – Record Q3'23 Adjusted EBITDA of $89.4 Million, Up 1...

5 months ago - GlobeNewsWire

Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023

STOUGHTON, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people li...

6 months ago - GlobeNewsWire

Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023

STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people li...

8 months ago - GlobeNewsWire

Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026

STOUGHTON, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people li...

8 months ago - GlobeNewsWire

Collegium Announces $50 Million Accelerated Share Repurchase Program

STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people li...

9 months ago - GlobeNewsWire

Collegium Reports Record 1H'23 Net Revenue of $280.3 Million, Up 35% Year-over-Year

– Q2'23 Net Revenue of $135.5 Million, Up 10% Year-over-Year – – Q2'23 GAAP Net Income of $13.0 Million – – Q2'23 Adjusted EBITDA of $85.8 Million, Up 21% Year-over-Year – – Board of Directors has Aut...

9 months ago - GlobeNewsWire

Collegium to Report Second Quarter 2023 Financial Results on August 3, 2023

STOUGHTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people li...

9 months ago - GlobeNewsWire

Collegium to Participate in Jefferies Healthcare Conference

STOUGHTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people li...

11 months ago - GlobeNewsWire

Collegium Reports First Quarter 2023 Financial Results

– Generated Record Net Revenue of $144.8 Million – – Delivered Record Belbuca ® and Xtampza ® ER Net Revenue – – Ended Q1'23 with Cash Balance of $269.5 Million – – Reaffirmed Full Year 2023 Guidance ...

1 year ago - GlobeNewsWire

Collegium to Report First Quarter 2023 Financial Results on May 4, 2023

STOUGHTON, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people l...

1 year ago - GlobeNewsWire

Collegium to Participate in 22nd Annual Needham Virtual Healthcare Conference

STOUGHTON, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people l...

1 year ago - GlobeNewsWire

Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results

– Generated Record Quarterly and Full-Year Net Revenue of $129.6 and $463.9 Million –

1 year ago - GlobeNewsWire

Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering

STOUGHTON, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the pricing of its offering of $210,000,000 aggregate principal amount of 2.875% conve...

1 year ago - GlobeNewsWire

Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering

STOUGHTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its intention to offer, subject to market and other conditions, $175,000,000 aggregate...

1 year ago - GlobeNewsWire

Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results

-Results at or above high-end of 2022 earnings guidance-

1 year ago - GlobeNewsWire

Collegium Provides 2023 Financial Guidance

– Product Revenues, Net Expected in the Range of $565.0 Million to $580.0 Million –

1 year ago - GlobeNewsWire

Appeals Court Affirms Validity of Collegium's Belbuca® Patents

Ruling bars ANDA filer Alvogen from entering market until 2032 patent expiry Ruling bars ANDA filer Alvogen from entering market until 2032 patent expiry

1 year ago - GlobeNewsWire

Collegium to Participate in Piper Sandler 34th Annual Healthcare Conference

STOUGHTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will partici...

1 year ago - GlobeNewsWire

Collegium Reports Third Quarter 2022 Financial Results

– Generated Record Net Revenue of $127.0 Million –

1 year ago - GlobeNewsWire

Collegium to Report Third Quarter 2022 Financial Results on November 3, 2022

STOUGHTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that it will report third qu...

1 year ago - GlobeNewsWire